On Monday, Candel Therapeutics Inc (NASDAQ: CADL) was -5.64% drop from the session before settling in for the closing price of $9.22. A 52-week range for CADL has been $1.16 – $14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. When this article was written, the company’s average yearly earnings per share was at -21.37%. With a float of $27.66 million, this company’s outstanding shares have now reached $32.13 million.
Let’s look at the performance matrix of the company that is accounted for 42 employees. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Candel Therapeutics Inc stocks. The insider ownership of Candel Therapeutics Inc is 37.81%, while institutional ownership is 16.09%. The most recent insider transaction that took place on Dec 16 ’24, was worth 7,500,000. In this transaction Director of this company bought 1,250,000 shares at a rate of $6.00, taking the stock ownership to the 1,303,752 shares. Before that another transaction happened on Nov 29 ’24, when Company’s Chief Technology Officer sold 20,392 for $4.56, making the entire transaction worth $92,898. This insider now owns 125,657 shares in total.
Candel Therapeutics Inc (CADL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -21.37% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
You can see what Candel Therapeutics Inc (CADL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Candel Therapeutics Inc (NASDAQ: CADL) saw its 5-day average volume 1.68 million, a negative change from its year-to-date volume of 1.69 million. As of the previous 9 days, the stock’s Stochastic %D was 58.70%. Additionally, its Average True Range was 1.24.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 45.45%, which indicates a significant decrease from 62.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 204.13% in the past 14 days, which was higher than the 149.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.00, while its 200-day Moving Average is $6.42. Nevertheless, the first resistance level for the watch stands at $9.23 in the near term. At $9.77, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.13. If the price goes on to break the first support level at $8.33, it is likely to go to the next support level at $7.97. The third support level lies at $7.43 if the price breaches the second support level.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
There are 32,476K outstanding shares of the company, which has a market capitalization of 396.83 million. As of now, sales total 0 K while income totals -37,940 K. Its latest quarter income was 0 K while its last quarter net income were -10,650 K.
